13F Holdings
中文EN

GMAB GENMAB A/S IFRS

Pharmaceutical Preparations · Nasdaq · SEC CIK 1434265

Financial factors as of 2025-12-31 (FY2025), by fiscal year; growth vs the previous fiscal year

Growth

TTM revenue YoY19.2%
TTM net income YoY-15.0%
TTM EPS YoY-12.3%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin93.6%
Operating margin28.6%
Net margin25.9%
FCF margin30.9%
EBITDA margin—

Returns

ROE17.5%
ROA10.0%
ROIC (approx.)12.9%
Asset turnover0.39x

Leverage & solvency

Liabilities / assets54.6%
Debt / equity0.90x
Current ratio2.02x
Interest coverage3.96x

Cash quality & payout

Operating cash flow / net income1.23x
Accruals ratio-2.3%
Payout ratio—
Capex / revenue1.0%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY2025*2025-12-31 · USDFY2024*2024-12-31 · USDFY2023*2023-12-31 · USDFY2019*2019-12-31 · DKKFY2018*2018-12-31 · DKK
Income statement
Revenue$3.72B$3.12B$2.39B5.37B3.02B
Cost of revenue$238.00M$143.00M$33.00M——
Gross profit$3.48B$2.98B$2.36B——
R&D expense$1.61B$1.41B$1.11B2.39B1.43B
SG&A expense$626.00M$549.00M$478.00M342.00M214.00M
Operating income$1.06B$972.00M$772.00M2.64B1.38B
Interest expense$269.00M$291.00M$254.00M7.00M11.00M
Pretax income$1.20B$1.33B$817.00M2.86B1.61B
Income tax$241.00M$193.00M$186.00M693.00M140.00M
Net income$963.00M$1.13B$631.00M2.17B1.47B
EBITDA———2.68B1.41B
EPS (basic)15.5017.669.6734.4024.03
EPS (diluted)15.3717.539.5834.0323.73
Weighted avg. shares (diluted)62.69M64.66M65.90M63.64M62.04M
Balance sheet
Cash & equivalents$1.72B$1.38B$2.20B3.55B533.00M
Receivables$1.11B$923.00M$733.00M2.99B1.33B
Inventory$18.00M$9.00M$8.00M——
Current assets$2.88B$3.90B$4.91B13.96B7.43B
PP&E, netmay include right-of-use assets (IFRS)$153.00M$137.00M$142.00M237.00M162.00M
Goodwill$355.00M$355.00M$0——
Intangibles$9.12B$1.73B$15.00M470.00M470.00M
Total assets$12.87B$6.41B$5.23B15.14B8.46B
Current liabilities$1.43B$744.00M$368.00M938.00M444.00M
Short-term debt$273.00M$0$0——
Long-term debt$5.00B$0$0——
Total debt$5.27B$0$0——
Total liabilities$7.03B$1.28B$545.00M1.10B447.00M
Shareholders' equity$5.85B$5.14B$4.69B14.05B8.01B
Net debt$3.56B-$1.38B-$2.20B——
Shares outstanding64.24M66.19M66.07M65.07M61.50M
Cash flow statement
Operating cash flow$1.19B$1.13B$1.07B1.33B1.01B
Capital expenditure$37.00M$27.00M$53.00M79.00M72.00M
Free cash flow$1.15B$1.10B$1.02B1.25B943.00M
Investing cash flow-$5.64B-$1.45B-$185.00M-1.98B-1.78B
Financing cash flow$4.79B-$566.00M-$89.00M3.66B-71.00M
Depreciation & amortization———40.00M28.00M
Stock-based compensation$128.00M$105.00M$85.00M147.00M91.00M

Free plan shows the latest 5 periods; Pro shows all 6 🔒

· This company reports under IFRS: some line items differ from US GAAP — operating income is not required, interest expense may be broader "finance costs", and banks have no standard revenue line.

· This company uses different currencies across periods or line items (e.g. USD convenience translations in annual reports). Each column header shows its currency and cells in a different currency are marked; do not compare figures across currencies. Charts use only periods in the latest period's currency.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.